The financial results published this week by the two main manufacturers of anti-Covid vaccines will surely give further arguments to supporters of the lifting of patents.
Pfizer and Moderna have posted spectacular quarterly revenues and revised their forecasts upwards.
Unlike AstraZeneca and Janssen who market their vaccine at cost, they have chosen to make a profit on the sale of their serum.
Moderna, which had never marketed a treatment until then, achieved 1.9 billion dollars in sales in the first quarter (against 8 million in the same period last year).
Read also:
Vaccines: laboratories consider the lifting of patents "unnecessary and harmful"
The American biotech has delivered 102 million doses of its vaccine, available in 37 countries.
But it is still in its infancy.
She expects to double in the second trimester.
Faced with the proliferation of variants and the growing needs of countries in the South, Moderna has just announced a new increase in its capacities which represents "
several billion
This article is for subscribers only.
You have 70% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in
